SE439306B - 4-amino-2-piperidinokinazolinderivat och farmaceutisk beredning derav - Google Patents

4-amino-2-piperidinokinazolinderivat och farmaceutisk beredning derav

Info

Publication number
SE439306B
SE439306B SE7904358A SE7904358A SE439306B SE 439306 B SE439306 B SE 439306B SE 7904358 A SE7904358 A SE 7904358A SE 7904358 A SE7904358 A SE 7904358A SE 439306 B SE439306 B SE 439306B
Authority
SE
Sweden
Prior art keywords
evaporated
chloroform
amino
piperidine
phenyl
Prior art date
Application number
SE7904358A
Other languages
English (en)
Swedish (sv)
Other versions
SE7904358L (sv
Inventor
S F Campbell
J C Danilewicz
C W Greengrass
R M Plews
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SE7904358L publication Critical patent/SE7904358L/xx
Publication of SE439306B publication Critical patent/SE439306B/sv

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SE7904358A 1978-05-18 1979-05-17 4-amino-2-piperidinokinazolinderivat och farmaceutisk beredning derav SE439306B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2035178 1978-05-18

Publications (2)

Publication Number Publication Date
SE7904358L SE7904358L (sv) 1979-11-19
SE439306B true SE439306B (sv) 1985-06-10

Family

ID=10144517

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7904358A SE439306B (sv) 1978-05-18 1979-05-17 4-amino-2-piperidinokinazolinderivat och farmaceutisk beredning derav

Country Status (30)

Country Link
US (1) US4243666A (es)
JP (1) JPS554370A (es)
AR (2) AR223487A1 (es)
AT (1) ATA363379A (es)
AU (1) AU512947B2 (es)
BE (1) BE876297A (es)
CA (1) CA1240325A (es)
CH (1) CH643553A5 (es)
CS (1) CS214796B2 (es)
DD (1) DD143613A5 (es)
DE (1) DE2919800A1 (es)
DK (1) DK159079A (es)
ES (2) ES480671A1 (es)
FI (1) FI64589C (es)
FR (1) FR2434162A1 (es)
GR (1) GR72824B (es)
HU (1) HU182562B (es)
IL (1) IL57297A (es)
IN (1) IN153045B (es)
IT (1) IT1114222B (es)
LU (1) LU81284A1 (es)
NL (1) NL172157C (es)
NO (1) NO791648L (es)
NZ (1) NZ190465A (es)
PH (1) PH14802A (es)
PL (2) PL121158B1 (es)
PT (1) PT69622A (es)
SE (1) SE439306B (es)
YU (2) YU115279A (es)
ZA (1) ZA792390B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4607034A (en) * 1979-10-29 1986-08-19 Mitsubishi Yuka Pharmaceutical Co., Ltd. Quinazoline derivatives and pharmaceutical composition thereof
JPS5962766U (ja) * 1982-06-30 1984-04-25 守田 智 小動物用給水器
GB8414518D0 (en) * 1984-06-07 1984-07-11 Pfizer Ltd Therapeutic agents
US5801195A (en) * 1994-12-30 1998-09-01 Celgene Corporation Immunotherapeutic aryl amides
US6248888B1 (en) 1997-11-14 2001-06-19 Teva Pharmaceutical Industries Ltd. Process for the preparation of terazosin hydrochloride dihydrate
WO2002057235A1 (fr) * 2001-01-18 2002-07-25 Takeda Chemical Industries, Ltd. Procede de preparation de composes de benzylpiperidine
US6746460B2 (en) * 2002-08-07 2004-06-08 Satiety, Inc. Intra-gastric fastening devices
WO2005042501A1 (en) * 2003-11-03 2005-05-12 Warner-Lambert Company Llc Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
AR063275A1 (es) * 2006-10-12 2009-01-14 Epix Delaware Inc Compuestos de carboxamida, una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la activacion de ccr2.
JP5524041B2 (ja) * 2007-04-04 2014-06-18 シプラ・リミテッド エルロチニブおよびその薬学的に許容可能な塩の製造方法
WO2009076512A1 (en) * 2007-12-11 2009-06-18 Epix Delaware, Inc. Carboxamidξ compounds and their use as chemokine receptor agonists
AU2009315761A1 (en) * 2008-11-14 2010-05-20 F. Hoffmann-La Roche Ag Quinazoline derivatives as NK3 receptor antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1156973A (en) * 1965-07-06 1969-07-02 Quinazoline Derivatives
US3511836A (en) * 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines
FR2321890A1 (fr) * 1975-08-26 1977-03-25 Synthelabo Nouveaux derives de la quinazoline, leurs sels, leur preparation et les medicaments qui en renferment
DK140695C (da) * 1976-05-07 1980-05-12 Synthelabo Analogifremgangsmaade til fremstilling af 2,4-diamino-6,7-dimethoxyquinazolinderivater eller syreadditionssalte heraf

Also Published As

Publication number Publication date
AU512947B2 (en) 1980-11-06
PL223844A1 (es) 1981-01-02
CH643553A5 (de) 1984-06-15
US4243666A (en) 1981-01-06
FR2434162B1 (es) 1983-04-22
ES488210A0 (es) 1980-12-16
ATA363379A (de) 1983-05-15
NO791648L (no) 1979-11-20
ZA792390B (en) 1980-07-30
NL172157B (nl) 1983-02-16
FR2434162A1 (fr) 1980-03-21
NL7903853A (nl) 1979-11-20
PT69622A (en) 1979-06-01
DE2919800A1 (de) 1979-11-22
GR72824B (es) 1983-12-06
JPS554370A (en) 1980-01-12
JPS5623992B2 (es) 1981-06-03
AR224784A1 (es) 1982-01-15
HU182562B (en) 1984-02-28
CA1240325A (en) 1988-08-09
LU81284A1 (fr) 1980-12-16
NL172157C (nl) 1983-07-18
SE7904358L (sv) 1979-11-19
IL57297A (en) 1983-02-23
DK159079A (da) 1979-11-19
IN153045B (es) 1984-05-26
ES480671A1 (es) 1980-08-16
YU256382A (en) 1983-04-30
DD143613A5 (de) 1980-09-03
FI791562A (fi) 1979-11-19
PL121158B1 (en) 1982-04-30
YU115279A (en) 1983-04-30
NZ190465A (en) 1981-05-01
AU4710179A (en) 1979-11-22
ES8101584A1 (es) 1980-12-16
IT1114222B (it) 1986-01-27
FI64589B (fi) 1983-08-31
PL215626A1 (es) 1980-08-25
PH14802A (en) 1981-12-14
CS214796B2 (en) 1982-05-28
AR223487A1 (es) 1981-08-31
IL57297A0 (en) 1979-09-30
BE876297A (fr) 1979-11-16
PL120651B1 (en) 1982-03-31
IT7922720A0 (it) 1979-05-16
FI64589C (fi) 1983-12-12

Similar Documents

Publication Publication Date Title
US6436928B1 (en) Selective neurokinin antagonists
DK171694B1 (da) Krystallinsk paroxetinhydrochlorid, farmaceutisk præparat indeholdende dette samt fremstilling deraf
JPH09500875A (ja) タキキニン拮抗薬としての4−フェニル−4−フェニルプロピル(エチル)−ピペリジン
SE439306B (sv) 4-amino-2-piperidinokinazolinderivat och farmaceutisk beredning derav
DE69221919T2 (de) Piperidin-Derivate
SU1313344A3 (ru) Способ получени @ -арил- @ -аминокарбоксамидов или их солей с фармацевтически приемлемой кислотой или возможной стереохимической изомерной формы
JPH05140103A (ja) 新規なn−アルキレンピペリジノ化合物及びそのエナンチオマー;これらを合成する方法及びこれらを含む医薬品組成物
EP1237874A2 (en) Selective neurokinin antagonists
HU193229B (en) Process for producing 1-benzyl-amino-methyl-pyrrolidinones and their acid addition salts
TW200303304A (en) Chemical compounds
GB2061272A (en) Morpholine Derivatives
NO822041L (no) N-oksacyklyl-alkylpiperidinderivater, fremgangsmaate til deres fremstilling, farmasoeytiske preparater inneholdende dem, og deres anvendelse
CA3014745A1 (en) Crystalline form of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine salt
CZ396591A3 (en) Enantiomers of 1,4-dihydropyridine process of their preparation and pharmaceutical compositions prepared therefrom
CA1203239A (en) Piperazine derivative, process for preparation thereof and analgesic composition containing the same
EP1368313A1 (de) Verfahren zur herstellung von nicht hydratisiertem fexofenadin-hydrochlorid und eine so erhaetliche neue kristalline form
DE69031111T2 (de) Indolderivate
NO179974B (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive piperidinforbindelser
HU193393B (en) Process for preparing new, substituted pyrrolidinones
WO2007062333A2 (en) New pleuromutilin derivative and its use
DE60222015T2 (de) Ccr-3-rezeptorantagonisten vii
EP0748806A1 (en) POLYMORPHS B AND C OF 1- 2,4-DICHLORO-BETA-[(7-CHLOROBENZO[b]THIEN-3-YL)METHOXY]PHENETYL]IMIDAZOLE MONONITRATE
EP3725774B1 (en) Process for the preparation of a pharmaceutical agent
CA2822767A1 (en) Polymorphs of 3-chloro-4[(2r)-2-(4-chlorophenyl)-4-[(1r)-1-(4-cyanophenyl)ethyl]-1-piperazinyl]-benzonitrile, pharmaceutical compositions and method of use comprising said polymorphs, and a process for preparing them
US10988473B2 (en) Process for the preparation of (3S,4S)-tetrahydrofuran-3-yl 4-isopropyl-6,7-dihydro-3H-imidazo[4,5-C]pyridine-5(4H)-carboxylate

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 7904358-4

Effective date: 19900518

Format of ref document f/p: F